Federated Hermes Inc. Sells 128,418 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Federated Hermes Inc. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 25.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 380,418 shares of the biotechnology company’s stock after selling 128,418 shares during the quarter. Federated Hermes Inc. owned approximately 0.40% of Sarepta Therapeutics worth $46,255,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Manchester Capital Management LLC lifted its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 156 shares during the period. Sunbelt Securities Inc. increased its stake in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new position in Sarepta Therapeutics in the fourth quarter worth approximately $36,000. Finally, Steward Partners Investment Advisory LLC grew its position in Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 194 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Trading Down 3.7 %

Sarepta Therapeutics stock opened at $52.40 on Tuesday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a 50-day moving average price of $95.66 and a 200 day moving average price of $113.09. Sarepta Therapeutics, Inc. has a 52 week low of $50.61 and a 52 week high of $173.25. The company has a market capitalization of $5.08 billion, a price-to-earnings ratio of 41.92 and a beta of 0.93.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research report on Wednesday, March 19th. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $161.00 to $87.00 in a research report on Monday, March 31st. Needham & Company LLC reduced their price objective on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating for the company in a research note on Thursday, April 3rd. Scotiabank cut their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a report on Thursday, March 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $163.18.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.